Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result

This article has no abstract
Epistemonikos ID: afb7d489808d295119a6024adbf3e31922b93b5c
First added on: Feb 07, 2025